Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Dudziec, Ewa ^a   Gogol Döring, Andreas ^b   Cookson, Victoria ^a   Chen, Wei ^b   Catto, James ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; MESSENGER RNA; HISTONE;

ARTICLE; BLADDER CANCER; CARCINOGENESIS; CELL FUNCTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE REPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC ASSOCIATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; METHYLATED DNA IMMUNOPRECIPITATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; POSITIVE FEEDBACK; STRATIFIED SAMPLE; TRANSITIONAL CELL CARCINOMA; CARCINOMA; CELL LINE; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; URETHRA TUMOR; UROTHELIUM;

CARCINOMA; CELL LINE; CLUSTER ANALYSIS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; RNA, MESSENGER; URETHRAL NEOPLASMS; UROTHELIUM;

EID: 84863281311     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032750     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E Cancer statistics (2010) CA Cancer. J Clin 60: 277-300.
2. van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, et al. (2009) FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 55: 650-657.
3. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A, (2009) An operational definition of epigenetics. Genes & development 23: 781-783.
4. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, et al. (2011) MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review. Eur Urol 59: 671-681.
5. Dudziec E, Miah S, Choudhry HM, Owen HC, Blizard S, et al. (2011) Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin Cancer Res 17: 1287-1296.
6. Kouzarides T, (2007) Chromatin modifications and their function. Cell 128: 693-705.
7. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, et al. (2007) High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837.
8. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, et al. (2008) Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genetics 40: 897-903.
9. Sharma S, Kelly TK, Jones PA, (2010) Epigenetics in cancer. Carcinogenesis 31: 27-36.
10. Fuks F, (2005) DNA methylation and histone modifications: teaming up to silence genes. Current Opinion Genetics & Dev 15: 490-495.
11. Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, et al. (2005) Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 23: 2903-2910.
12. Catto JW, Miah S, Owen HC, Bryant H, Dudziec E, et al. (2009) Distinct microRNA alterations characterize high and low grade bladder cancer. Cancer Res 69: 8472-8481.
13. Dhawan D, Hamdy FC, Rehman I, Patterson J, Cross SS, et al. (2006) Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 209: 336-343.
14. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, et al. (2007) Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 13: 2046-2053.
15. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, et al. (2009) The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genetics 41: 178-186.
16. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
17. Hulsen T, de Vlieg J, Alkema W, (2008) BioVenn- a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC genomics 9: 488.
18. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, et al. (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64: 4040-4048.
19. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, et al. (2010) Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 9: 3.
20. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, et al. (2005) Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11: 8570-8576.
21. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, et al. (2009) Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genetics 41: 521-523.
22. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, et al. (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genetics 39: 232-236.
23. Rush M, Appanah R, Lee S, Lam LL, Goyal P, et al. (2009) Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation. Epigenetics 4: 404-414.
24. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, et al. (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genetics 40: 741-750.
25. Knowles MA, Aveyard JS, Taylor CF, Harnden P, Bass S, (2005) Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Letters 225: 121-130.
26. Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, et al. (1999) The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci USA 96: 3928-3933.
27. Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, et al. (1995) Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 55: 3228-3232.
28. Gould JJ, Kenney PA, Rieger-Christ KM, Silva Neto B, Wszolek MF, et al. (2010) Identification of tumor and invasion suppressor gene modulators in bladder cancer by different classes of histone deacetylase inhibitors using reverse phase protein arrays. J Urol 183: 2395-2402.
29. Behrens P, Brinkmann U, Wellmann A, (2003) CSE1L/CAS: its role in proliferation and apoptosis. Apoptosis 8: 39-44.
30. Tanaka T, Ohkubo S, Tatsuno I, Prives C, (2007) hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell 130: 638-650.
31. Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK, (1994) Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest 71: 583-594.
32. Catto JW, Azzouzi AR, Amira N, Rehman I, Feeley KM, et al. (2003) Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene 22: 8699-8706.
33. Adamidi C, Wang Y, Gruen D, Mastrobuoni G, You X, et al. (2011) De novo assembly and validation of planaria transcriptome by massive parallel sequencing and shotgun proteomics. Genome Res 21: 1193-1200.
34. Langmead B, (2010) Aligning short sequencing reads with Bowtie. Current protocols in bioinformatics/editoral board, Andreas D Baxevanis [et al] Chapter 11: Unit 11 17.
35. Mohn F, Weber M, Schubeler D, Roloff TC, (2009) Methylated DNA immunoprecipitation (MeDIP). Methods Mol Biol 507: 55-64.
36. Ferraiuolo L, Heath PR, Holden H, Kasher P, Kirby J, et al. (2007) Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J Neurosci 27: 9201-9219.